Lilly Eli & Co Stock Price, News & Analysis

Eli Lilly and Company (NYSE: LLY) will host a webcast on July 1, 2021, at 10:00 a.m. Eastern Time, to discuss its diabetes portfolio and findings from the tirzepatide SURPASS clinical trial at the American Diabetes Association's Virtual 81st Scientific Sessions. The conference will address next steps for tirzepatide and insights on Lilly's once-weekly basal insulin and early-phase incretins. The event will be accessible via Lilly's investor website, with a replay available afterward.

Eli Lilly announced promising data for Verzenio (abemaciclib) in high-risk early breast cancer and the oral selective estrogen receptor degrader LY3484356 at ASCO 2021. In the Phase 3 monarchE trial, Verzenio combined with endocrine therapy decreased recurrence risk by 38.6% in patients post-neoadjuvant chemotherapy. The trial included 2,056 patients, with a two-year invasive disease-free survival rate of 87.2%. LY3484356's Phase 1a trial showed encouraging safety and efficacy in advanced breast cancer, with a planned Phase 3 study (EMBER-3) to start later this year.

Eli Lilly will attend the Goldman Sachs Healthcare Conference on June 9-10, 2021. Key executives, including Anne White and Jake Van Naarden, will host a virtual fireside chat on June 9 at 8:50 a.m. ET. The session will be accessible via a live audio webcast on Lilly's Investor website, with a replay available for approximately 90 days.

Lilly is committed to developing life-changing medicines and improving disease management worldwide. For more information, visit www.lilly.com.

Eli Lilly and Company (NYSE: LLY) presented findings on migraine care at the AHS 2021 meeting, revealing 45% of participants hesitated to seek treatment. Key insights from the OVERCOME study highlighted barriers to optimal care. Emgality showed greater adherence (51.2%) compared to oral preventive treatments (27.6%). A discrete choice experiment demonstrated patient preference for the Emgality auto-injector. Additionally, REYVOW 100 mg and 200 mg exhibited superior efficacy in pain relief compared to Nurtec and UBRELVY. These findings underscore the need for improved migraine care discussions.

Eli Lilly and Incyte presented data at the EULAR Congress indicating that OLUMIANT® (baricitinib) 4 mg significantly reduced pain and morning joint stiffness while enhancing physical function at 12 weeks in moderate to severe rheumatoid arthritis patients compared to HUMIRA® (adalimumab) and placebo. The analysis, based on the Phase 3 RA-BEAM study with 1,305 participants, highlighted improved patient-reported outcomes and consistent safety results. OLUMIANT is approved in over 75 countries for RA treatment and recently received approval in Japan for COVID-19 pneumonia.

Eli Lilly and Company (NYSE: LLY) is set to present new data from Phase 3 studies at the virtual EULAR Congress (June 2-5, 2021), demonstrating Taltz's long-term efficacy and safety in axial spondyloarthritis (axSpA). In the COAST-Y study, continuous Taltz treatment showed that 56.7% of patients achieved ASAS40 after two years. Additionally, 89.6% of patients experienced no bone damage progression. Taltz has treated over 175,000 patients globally, supporting its use for multiple inflammatory conditions.

Eli Lilly's Phase 2 SERENITY study revealed that mirikizumab significantly alleviates fatigue in patients suffering from moderately to severely active Crohn's disease. At 12 weeks, patients receiving mirikizumab showed marked improvements in FACIT-Fatigue scores compared to placebo. This positive effect was sustained over one year. The study underscores the significance of fatigue as a symptom that correlates with disease activity and quality of life. This data is being showcased at Digestive Disease Week (DDW) 2021, reaffirming the need for innovative treatments for inflammatory bowel diseases.

Eli Lilly's tirzepatide achieved significant A1C and body weight reductions in adults with type 2 diabetes at increased cardiovascular risk in the SURPASS-4 clinical trial. The highest dose showed an A1C reduction of 2.58% and a weight loss of 11.7 kg compared to insulin glargine, which had an A1C reduction of 1.44% and weight gain. The study met all primary and secondary endpoints, demonstrating the potential of tirzepatide as a treatment option. A regulatory submission is planned by the end of 2021.

New data from Eli Lilly's oncology portfolio will be showcased at the 2021 ASCO Annual Meeting from June 4-8, 2021. Key highlights include a subgroup analysis of Verzenio® (abemaciclib) from the Phase 3 monarchE trial focused on hormone receptor-positive breast cancer and a first look at clinical data for Lilly's oral selective estrogen receptor degrader. Additionally, updates on Retevmo® (selpercatinib) for lung and thyroid cancer will be presented, alongside findings related to CYRAMZA® and ERBITUX® in gastrointestinal cancers, emphasizing treatment outcomes and patient demographics.